Phase I proof-of-concept data presented at last week's American Society of Clinical Oncology meeting in Chicago suggest the next wave of immunotherapies in melanoma could generate better tumor responses than Yervoy ipilimumab with the same or better safety profile. Yervoy is a first-generation mAb immune checkpoint inhibitor that targets CTLA-4 (CD152). It was approved in 2011 and is marketed by Bristol-Myers Squibb Co. (NYSE:BMY) to treat unresectable or metastatic melanoma. At ASCO, new checkpoint inhibitor mAbs from BMS, Merck & Co. Inc.